|
US5618920A
(en)
*
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
|
US4902505A
(en)
*
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4801575A
(en)
*
|
1986-07-30 |
1989-01-31 |
The Regents Of The University Of California |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4946778A
(en)
*
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5530101A
(en)
*
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5180820A
(en)
*
|
1989-08-30 |
1993-01-19 |
Barde Yves Alain |
Brain-derived neurotrophic factor
|
|
US5229500A
(en)
*
|
1989-08-30 |
1993-07-20 |
Regeneron Pharmaceuticals, Inc. |
Brain derived neurotrophic factor
|
|
NZ235148A
(en)
*
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
|
US6541610B1
(en)
*
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
|
US6329508B1
(en)
*
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
|
US5154924A
(en)
*
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
|
EP1132471A3
(de)
*
|
1989-09-12 |
2001-11-28 |
F. Hoffmann-La Roche Ag |
TNF-bindende Proteine
|
|
TW279133B
(enExample)
*
|
1990-12-13 |
1996-06-21 |
Elan Med Tech |
|
|
US5527288A
(en)
*
|
1990-12-13 |
1996-06-18 |
Elan Medical Technologies Limited |
Intradermal drug delivery device and method for intradermal delivery of drugs
|
|
US6060069A
(en)
|
1991-05-20 |
2000-05-09 |
Dura Pharmaceuticals, Inc. |
Pulmonary delivery of pharmaceuticals
|
|
US6287792B1
(en)
*
|
1991-06-17 |
2001-09-11 |
The Regents Of The University Of California |
Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
|
|
EP0528767B1
(en)
*
|
1991-08-21 |
2000-01-12 |
Novartis AG |
Antibody derivatives
|
|
ATE275197T1
(de)
*
|
1991-09-20 |
2004-09-15 |
Amgen Inc |
Glial neurotrophe faktor
|
|
JPH06228199A
(ja)
|
1992-11-27 |
1994-08-16 |
Takeda Chem Ind Ltd |
血液脳関門通過可能なペプチド結合体
|
|
CA2115900A1
(en)
|
1993-02-22 |
1994-08-23 |
Gerald W. Becker |
Pharmaceutical screens and antibodies
|
|
US5997501A
(en)
|
1993-11-18 |
1999-12-07 |
Elan Corporation, Plc |
Intradermal drug delivery device
|
|
ATE208633T1
(de)
*
|
1994-09-16 |
2001-11-15 |
Merck Patent Gmbh |
Immunokonjugate
|
|
US5656284A
(en)
*
|
1995-04-24 |
1997-08-12 |
Balkin; Michael S. |
Oral transmucosal delivery tablet and method of making it
|
|
AU6163196A
(en)
*
|
1995-06-07 |
1996-12-30 |
Smithkline Beecham Corporation |
Method for obtaining receptor agonist antibodies
|
|
AU719613B2
(en)
*
|
1995-09-19 |
2000-05-11 |
Astellas Pharma Inc. |
Aerosol compositions
|
|
US6015662A
(en)
*
|
1996-01-23 |
2000-01-18 |
Abbott Laboratories |
Reagents for use as calibrators and controls
|
|
US5837231A
(en)
*
|
1996-06-27 |
1998-11-17 |
Regents Of The University Of Minnesota |
GM-CSF administration for the treatment and prevention of recurrence of brain tumors
|
|
CA2261032C
(en)
|
1996-07-16 |
2003-11-25 |
De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur |
Dibenzodihydropyridinecarboxylic esters and their use in chemiluminescent assay methods
|
|
US8173127B2
(en)
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
|
AU8269898A
(en)
|
1997-06-27 |
1999-01-19 |
Regents Of The University Of California, The |
Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
|
|
WO1999000951A1
(en)
|
1997-06-30 |
1999-01-07 |
Motorola Inc. |
Circuit and packet switched network interconnection
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US6482923B1
(en)
|
1997-09-17 |
2002-11-19 |
Human Genome Sciences, Inc. |
Interleukin 17-like receptor protein
|
|
US6165783A
(en)
*
|
1997-10-24 |
2000-12-26 |
Neuro Spheres Holdings Ltd. |
Erythropoietin-mediated neurogenesis
|
|
US6016800A
(en)
*
|
1997-10-24 |
2000-01-25 |
Century; Theodore J. |
Intrapulmonary aerosolizer
|
|
US6743427B1
(en)
*
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
CN1206004C
(zh)
|
1997-12-11 |
2005-06-15 |
阿尔扎有限公司 |
增强透皮物剂流量的装置
|
|
PT1071700E
(pt)
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
|
JP4113670B2
(ja)
|
1998-06-22 |
2008-07-09 |
イムノメディクス， インコーポレイテッド |
プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用
|
|
US6348210B1
(en)
*
|
1998-11-13 |
2002-02-19 |
Alza Corporation |
Methods for transdermal drug administration
|
|
US6375975B1
(en)
*
|
1998-12-21 |
2002-04-23 |
Generex Pharmaceuticals Incorporated |
Pharmaceutical compositions for buccal and pulmonary application
|
|
ATE300957T1
(de)
|
1998-12-22 |
2005-08-15 |
Genentech Inc |
Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
|
|
US6284262B1
(en)
*
|
1999-01-26 |
2001-09-04 |
Virgil A. Place |
Compact dosage unit for buccal administration of a pharmacologically active agent
|
|
US7214658B2
(en)
*
|
2004-07-06 |
2007-05-08 |
Tact Ip, Llc |
Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
|
|
AU3512300A
(en)
|
1999-03-05 |
2000-09-21 |
Epigenesis Pharmaceuticals, Inc. |
Method for validating/invalidating target(s) and pathways
|
|
US7410941B1
(en)
*
|
1999-04-13 |
2008-08-12 |
The Kenneth S. Warren Institute, Inc. |
Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
|
|
ATE405636T1
(de)
*
|
1999-06-16 |
2008-09-15 |
Boston Biomedical Res Inst |
Immunologische kontrolle des beta-amyloid gehaltes in vivo
|
|
CZ299516B6
(cs)
*
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
|
US20020052311A1
(en)
*
|
1999-09-03 |
2002-05-02 |
Beka Solomon |
Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
|
|
JP3589912B2
(ja)
*
|
1999-09-03 |
2004-11-17 |
泰久 福井 |
ホスファチジルイノシトール−３，４−二リン酸を認識するモノクローナル抗体
|
|
US6195605B1
(en)
|
1999-09-29 |
2001-02-27 |
Bmi Technologies Inc. |
Impact monitor
|
|
US6585971B1
(en)
*
|
1999-11-12 |
2003-07-01 |
Harbor-Ucla Research And Education Institute |
Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
|
|
EP2298333A3
(en)
|
1999-12-20 |
2012-05-02 |
Immunex Corporation |
Tweak receptor
|
|
US6248262B1
(en)
*
|
2000-02-03 |
2001-06-19 |
General Electric Company |
Carbon-reinforced thermoplastic resin composition and articles made from same
|
|
JP2003531582A
(ja)
*
|
2000-02-29 |
2003-10-28 |
レキシコン・ジェネティクス・インコーポレーテッド |
ヒトトランスポータータンパクおよびそれをコードするポリヌクレオチド
|
|
US6372250B1
(en)
*
|
2000-04-25 |
2002-04-16 |
The Regents Of The University Of California |
Non-invasive gene targeting to the brain
|
|
US6696274B2
(en)
*
|
2000-05-03 |
2004-02-24 |
Supratek Pharma, Inc. |
Ligand for enhancing oral and CNS delivery of biological agents
|
|
US7078376B1
(en)
*
|
2000-08-11 |
2006-07-18 |
Baxter Healthcare S.A. |
Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
|
|
US20030165853A1
(en)
*
|
2000-12-04 |
2003-09-04 |
The Regents Of The University Of California Office Of Technology Transfer |
Antisense imaging of gene expression of the brain in vivo
|
|
US6908902B2
(en)
*
|
2001-02-02 |
2005-06-21 |
Ortho-Mcneil Pharmaceutical, Inc. |
Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
|
|
PL362411A1
(en)
*
|
2001-02-06 |
2004-11-02 |
Merck Patent Gmbh |
Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
|
|
US8163289B2
(en)
|
2001-03-09 |
2012-04-24 |
Iterative Therapeutics, Inc. |
Methods and compositions involving polymeric immunoglobulin fusion proteins
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
US7629309B2
(en)
|
2002-05-29 |
2009-12-08 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
US20040005309A1
(en)
|
2002-05-29 |
2004-01-08 |
Symbiontics, Inc. |
Targeted therapeutic proteins
|
|
ES2300439T3
(es)
|
2001-04-30 |
2008-06-16 |
Zystor Therapeutics , Inc. |
Reconocimiento subcelular de proteinas terapeuticas.
|
|
US20030129186A1
(en)
*
|
2001-07-25 |
2003-07-10 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for modulating blood-brain barrier transport
|
|
EP1944040B1
(en)
*
|
2001-08-17 |
2012-08-01 |
Washington University |
Assay method for Alzheimer's disease
|
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
|
US20030072761A1
(en)
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
|
CA2463473A1
(en)
|
2001-10-16 |
2003-04-24 |
Symbiontics Inc. |
Targeted therapeutic proteins
|
|
US7053202B2
(en)
*
|
2001-10-19 |
2006-05-30 |
Millennium Pharmaceuticals, Inc. |
Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
|
|
EP1514106A4
(en)
|
2002-05-29 |
2007-05-09 |
Zystor Therapeutics Inc |
TARGETED THERAPEUTIC PROTEINS
|
|
DE60305919T2
(de)
|
2002-06-28 |
2007-01-18 |
Domantis Limited, Cambridge |
Dual-specifische liganden mit erhöhter halbwertszeit
|
|
US20040102369A1
(en)
*
|
2002-11-27 |
2004-05-27 |
The Regents Of The University Of California |
Transport of basic fibroblast growth factor across the blood brain barrier
|
|
US7388079B2
(en)
*
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
|
US20050142141A1
(en)
*
|
2002-11-27 |
2005-06-30 |
Pardridge William M. |
Delivery of enzymes to the brain
|
|
CN110496230A
(zh)
*
|
2003-02-11 |
2019-11-26 |
夏尔人类遗传性治疗公司 |
使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
|
|
AU2003286870A1
(en)
|
2003-06-05 |
2005-01-04 |
Salk Institute For Biological Studies |
Targeting polypeptides to the central nervous system
|
|
US20050026823A1
(en)
*
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
|
AU2004252171B2
(en)
|
2003-06-27 |
2011-04-21 |
Biogen Ma Inc. |
Modified binding molecules comprising connecting peptides
|
|
US7294704B2
(en)
*
|
2003-08-15 |
2007-11-13 |
Diadexus, Inc. |
Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
|
|
EP1548031A1
(en)
*
|
2003-12-22 |
2005-06-29 |
Dubai Genetics FZ-LLC |
Nature-identical erythropoietin
|
|
EP2532742B1
(en)
*
|
2004-01-30 |
2018-08-08 |
Shire Pharmaceuticals Ireland Limited |
Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject
|
|
CN1922313B
(zh)
|
2004-02-10 |
2011-10-26 |
生物马林医药公司 |
酸性α-糖苷酶及其片段
|
|
US7939490B2
(en)
*
|
2004-12-13 |
2011-05-10 |
University Of Maryland, Baltimore |
TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
|
|
WO2006074399A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
|
WO2006081171A1
(en)
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
|
JP5137814B2
(ja)
|
2005-04-06 |
2013-02-06 |
ジェンザイム・コーポレーション |
治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
|
|
EP1897940A4
(en)
|
2005-05-02 |
2009-04-15 |
Toray Industries |
COMPOSITION AND METHOD FOR DIAGNOSIS OF CREAM CANCER AND METASTASIS OF CREAM CANCER
|
|
EA014513B1
(ru)
*
|
2005-08-03 |
2010-12-30 |
Иммьюноджен, Инк. |
Композиция иммуноконъюгата
|
|
US8124076B2
(en)
|
2005-08-18 |
2012-02-28 |
Ramot At Tel Aviv University Ltd. |
Single chain antibodies against β-amyloid peptide
|
|
WO2007044468A2
(en)
|
2005-10-05 |
2007-04-19 |
The Cbr Institute For Biomedical Research, Inc. |
Method to treat flavivirus infection with sirna
|
|
US8142781B2
(en)
*
|
2005-10-07 |
2012-03-27 |
Armagen Technologies, Inc. |
Fusion proteins for blood-brain barrier delivery
|
|
US8741260B2
(en)
|
2005-10-07 |
2014-06-03 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of GDNF to the CNS
|
|
US8124095B2
(en)
*
|
2005-10-07 |
2012-02-28 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of erythropoietin to the CNS
|
|
CN101292036B
(zh)
*
|
2005-10-21 |
2016-04-13 |
弗·哈夫曼-拉罗切有限公司 |
用于重组表达多肽的方法
|
|
WO2007091250A2
(en)
|
2006-02-06 |
2007-08-16 |
The Medical Research And Infrastructure Fund Of The Tel-Aviv Sourasky Medical Center |
Enzyme replacement therapy for treating lysosomal storage diseases
|
|
US7981417B2
(en)
|
2006-06-07 |
2011-07-19 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting anti-bodies
|
|
US7744879B2
(en)
|
2006-06-07 |
2010-06-29 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting antibodies
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
US8497246B2
(en)
*
|
2006-08-18 |
2013-07-30 |
Armagen Technologies, Inc. |
Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
|
|
US9388425B2
(en)
|
2006-10-20 |
2016-07-12 |
Trustees Of Boston University |
Tunable genetic switch for regulating gene expression
|
|
JP2010510794A
(ja)
*
|
2006-11-28 |
2010-04-08 |
ハナル ファーマシューティカル カンパニー リミテッド |
修飾型エリスロポエチンポリペプチド及びこの治療用用途
|
|
DE202007003495U1
(de)
*
|
2007-03-08 |
2007-07-05 |
Rieter Automatik Gmbh |
Vorrichtung zur Erzeugung von Granulatkörnern aus einer Kunststoffschmelze
|
|
WO2008151841A2
(en)
*
|
2007-06-15 |
2008-12-18 |
University Of Zurich |
Treatment for alzheimer' s disease
|
|
EP2997976A1
(en)
|
2007-07-27 |
2016-03-23 |
Armagen Technologies, Inc. |
Methods and compositions for increasing alpha-l-iduronidase activity in the cns
|
|
WO2009070597A2
(en)
|
2007-11-26 |
2009-06-04 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of gdnf to the cns
|
|
HRP20170698T1
(hr)
|
2008-05-07 |
2017-09-22 |
Biomarin Pharmaceutical Inc. |
Lizosomski usmjereni peptidi i njihove uporabe
|
|
WO2010003101A2
(en)
|
2008-07-02 |
2010-01-07 |
Trubion Pharmaceuticals, Inc. |
Il6 immunotherapeutics
|
|
US20100077498A1
(en)
*
|
2008-09-11 |
2010-03-25 |
Pardridge William M |
Compositions and methods for blood-brain barrier delivery in the mouse
|
|
US20100098693A1
(en)
*
|
2008-10-07 |
2010-04-22 |
Pardridge William M |
Compositions and methods for blood-brain barrier delivery of organophosphatases
|
|
CN102300987A
(zh)
|
2008-12-17 |
2011-12-28 |
安吉奥开米公司 |
膜型-1基质金属蛋白抑制剂及其用途
|
|
JP5873003B2
(ja)
|
2009-03-18 |
2016-03-01 |
アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． |
ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
|
|
CA2765889A1
(en)
|
2009-06-24 |
2010-12-29 |
Opko Curna, Llc |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
|
JP2013507131A
(ja)
|
2009-10-09 |
2013-03-04 |
アーメイゲン・テクノロジーズ・インコーポレイテッド |
Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
|
|
PT2588130T
(pt)
|
2010-06-25 |
2016-11-25 |
Shire Human Genetic Therapies |
Entrega de agentes terapêuticos no cns
|
|
MX2013000324A
(es)
|
2010-06-25 |
2013-02-01 |
Shire Human Genetic Therapies |
Tratamiento del sindrome de sanfilippo tipo b.
|
|
UA115649C2
(uk)
|
2010-06-25 |
2017-12-11 |
Шае Хюмен Дженетік Терапіс, Інк. |
Способи та композиції для доставки до цнс ідуронат-2-сульфатази
|
|
BR112012033197A2
(pt)
|
2010-06-25 |
2017-06-06 |
Shire Human Genetic Therapies |
métodos e composições para liberação de cns de n-sulfatase de heparano.
|
|
BR112013013083A2
(pt)
|
2010-11-30 |
2016-12-13 |
Genentech Inc |
métodos para transportar um composto, para aumentar exposição do cns a um composto, para diminuir a depuração de um composto, para aumentar a retenção no cns de um composto, para otimizar a farmacocinética, para tratar um distúrbio neurológico em um mamífero, para desenvolver um anticorpo, anticorpo, fragmento de anticorpo, anticorpo multiespecífico e uso de um anticorpo
|
|
US8580922B2
(en)
|
2011-03-04 |
2013-11-12 |
Shire Human Genetic Therapies, Inc. |
Peptide linkers for polypeptide compositions and methods for using same
|
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
WO2012177997A1
(en)
|
2011-06-22 |
2012-12-27 |
The General Hospital Corporation |
Treatment of proteinopathies
|
|
US8859256B2
(en)
|
2011-10-05 |
2014-10-14 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
RU2014117291A
(ru)
|
2011-10-12 |
2015-11-20 |
Синаджева Биофарма Корп. |
Рекомбинантный человеческий белок naglu и его применение
|
|
US8486399B2
(en)
*
|
2011-12-02 |
2013-07-16 |
Armagen Technologies, Inc. |
Methods and compositions for increasing arylsulfatase A activity in the CNS
|
|
WO2013181454A1
(en)
|
2012-05-30 |
2013-12-05 |
Biostrategies LC |
Plant lectins as carriers of associated drug substances into animal and human cells
|
|
KR101380740B1
(ko)
|
2012-06-29 |
2014-04-11 |
쉐어 휴먼 제네텍 세러피스, 인코포레이티드 |
이듀로네이트-2-설파타제의 정제
|
|
US9540442B2
(en)
|
2012-08-02 |
2017-01-10 |
Jn Biosciences Llc |
Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
|
|
EP2910632B1
(en)
|
2012-10-19 |
2017-07-05 |
Tokushima University |
Highly functional enzyme having modified substrate specificity of human beta-hexosaminidase b and exhibiting protease resistance
|
|
US20140354655A1
(en)
|
2013-06-04 |
2014-12-04 |
Qualcomm Mems Technologies, Inc. |
Reducing floating node leakage current with a feedback transistor
|
|
US10906981B2
(en)
|
2013-07-19 |
2021-02-02 |
The Regents Of The University Of California |
Compositions and methods related to structures that cross the blood brain barrier
|
|
WO2015012944A1
(en)
|
2013-07-22 |
2015-01-29 |
Armagen Technologies, Inc |
Methods and compositions for increasing enzyme activity in the cns
|
|
PL3119892T3
(pl)
|
2014-03-17 |
2021-11-29 |
The Hospital For Sick Children |
Warianty białka beta-heksozaminidazy oraz związane z nimi sposoby do leczenia gangliozydoz gm2
|
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
|
TWI761413B
(zh)
|
2016-12-26 |
2022-04-21 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
|
WO2018124277A1
(ja)
|
2016-12-28 |
2018-07-05 |
Ｊｃｒファーマ株式会社 |
凍結乾燥製剤
|